Vivolight Medical Wins “Black Technology” Innovation Award for 355nm Cold Laser Technology

A Remarkable Win at the 8th Secret Light Awards

On June 4, 2025, Vivolight Medical won the Cutting-Edge Innovation Award at the 8th Secret Light Awards (SLA) held at Hilton Shenzhen World Exhibition & Convention Center. Its 355 nm cold-laser plaque-ablation system was chosen from among 20 finalists, marking a significant advance in medical-grade laser therapy.

About the Secret Light Awards (SLA)

The Secret Light Awards (SLA) is a premier, industry-wide honor in the laser sector, jointly established by the China Laser Industry Innovation Contribution Award Committee and Laser Manufacturing Network, in collaboration with multiple domestic laser industry associations, academic alliances, and industry medias.

The Secret Light Awards (SLA) has become recognition for technology advances and real-world applications in China’s laser field. With its credibility, it’s widely seen as the top honor in the business, earning thumbs-up across the industry.

Pioneering with 355nm Cold Laser Technology

Vivolight’s system features an innovative tripled-frequency Nd:YAG design that tackles challenges in high-energy coupling, beam transmission and shaping. Its compact design integrates real-time energy feedback, providing the stability and precision required for intravascular plaque ablation.

Key Advantages Compared to Traditional Technologies

Compared to the widely used 308nm excimer lasers, Vivolight’s 355nm solid-state cold laser offers below features:

Effective

• Greater plaque ablation efficiency

Safe

• The photochemical effect selectively targets plaques
• Lower thermal effect with minimal vascular wall damage
• Lower risk of vascular perforation

Convenient

• Ultra-compact design with lower weight
• No need for catheter alignment
• Reduced maintenance
• Instant readiness

These advantages establish the 355nm solid-state cold laser as a superior, minimally invasive option for both preclinical research and vascular interventions.

Clinical Applications and Market Outlook

Peripheral Artery Disease (PAD)

The pre-market clinical trial for lower extremity artery lesions has been completed. This system is on schedule to obtain China NMPA approval in Q1 2026.

Coronary Artery Disease (CAD)

As the first 355nm cold laser for coronary use, indications include:

• Chronic total occlusion (CTO) recanalization
• In-stent restenosis (ISR) treatment
• Management of balloon-resistant lesions
• Treatment of balloon-uncrossable lesions and bypass graft lesions

With clinical enrollment of coronary lesions nearing completion, the system aims to support a new paradigm of implant-free intervention strategies.

Driving Innovation in Medical Laser Technology

Winning the Cutting-Edge Innovation Award underscores Vivolight Medical’s dedication to pushing the boundaries of laser therapy. The company remains committed to advancing its R&D pipeline, strengthening strategic clinical collaborations, and accelerating the translation of technological breakthroughs into clinically meaningful solutions for patients worldwide.